Clinical Trial Update: Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites [Phase 2]

View source ↗

Summary

Completed Phase 2 safety study evaluating a second intraperitoneal infusion cycle of catumaxomab in patients with malignant ascites due to epithelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Carcinoma
• Malignant Ascites

Drugs mentioned

• Catumaxomab (Catumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: Malignant Ascites Due to Epithelial Carcinoma | Phase 2 | Status: COMPLETED